This story originally ran on March 4.

A new company, Ubiquigent, has been formed to develop reagents and kits to help "advance understanding of the biology of the ubiquitin proteasome pathway."

Based in Dundee, Scotland, Ubiquigent is operating as a subsidiary of stem cell firm Stemgent, which plans to invest $4.5 million into Ubiquigent over the next three years.

Stemgent is based in Boston and San Diego. Ubiquigent is Stemgent's first overseas company.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.